More on drug marketing and Big Pharma’s approach to patients and profits.
In 1996, Zyprexa was approved for the treatment of adults with schizophrenia, and a few years later, it was approved for short-term treatment of adults with manic episodes associated with bipolar disorder.
Yet despite these extremely limited approved uses, Zyprexa went on to become the top selling antipsychotic worldwide with an estimated 20 million people having used the drug and Lilly’s best-selling product, with $4.2 billion in sales in 2005, which translates into 30% of its total revenues.
The problem is, it’s actually not very good for patients’ health (an understatement) and Lilly is keen ($4.2billion a year keen) to stop the world from finding out the truth.
If you want to find out more about Zprexa and the way that Big Pharma operates, perhaps you might begin here.